bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods S1 from Systemic Biological Mechanisms of Neurocognitive Dysfunction in Long-Term Survivors of Childhood Hodgkin Lymphoma
Authors: Williams AnnaLynn M. , Liu Wei , Ehrhardt Matthew J. , Mirzaei Salehabadi Sedigheh , Panoskaltsis-Mortari Angela , Phillips Nicholas S. , Mulrooney Daniel A. , Flerlage Jamie E. , Yasui Yutaka , Srivastava Deokumar , Robison Leslie L. , Hudson Melissa M. , Ness Kirsten K. , Sabin Noah D. , Krull Kevin R.
Published: May 2024

Supplementary Methods
Figure S1-S7 from PPARα Agonism Enhances Immune Response to Radiotherapy While Dietary Oleic Acid Results in Counteraction
Authors: Ross Richard Blake , Gadwa Jacob , Yu Justin , Darragh Laurel B. , Knitz Michael W. , Nguyen Diemmy , Olimpo Nicholas A. , Abdelazeem Khalid N.M. , Nguyen Alexander , Corbo Sophia , Van Court Benjamin , Beynor Jessica , Neupert Brooke , Saviola Anthony J. , D'Alessandro Angelo , Karam Sana D.
Published: May 2024

Supplemental figures
Supplementary Figure 3 from Optimizing Cervical Target Volume in Patients with Nasopharyngeal Cancer Based On Nodal Drainage Distance
Authors: Liu Yang , Yan Wenbin , Hu Chaosu , Huang Xiaodong , Wang Kai , Qu Yuan , Chen Xuesong , Wu Runye , Zhang Ye , Zhang Jianghu , Luo Jingwei , Li Yexiong , Wang Jingbo , Yi Junlin
Published: May 2024

The impact of Epstein-Barr virus (EBV) DNA copies on nodal drainage distance.
Supplementary Table S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Table S3. Supplementary Table S3. Representativeness of study participants.
Supplemental Table 3 from Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
Authors: Kandarpa Malathi , Robinson Dan , Wu Yi-Mi , Qin Tingting , Pettit Kristen , Li Qing , Luker Gary , Sartor Maureen , Chinnaiyan Arul , Talpaz Moshe
Published: May 2024

Supplemental Table 3. Gene Variants in ET/PV/PrePMF
Supplementary Figure S3 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
Authors: Svanberg Teglgaard Rebecca , Marquart Hanne Vibeke , Hartling Hans Jakob , Bay Jakob Thaning , da Cunha-Bang Caspar , Brieghel Christian , Faitová Tereza , Enggaard Lisbeth , Kater Arnon P. , Levin Mark-David , Kersting Sabina , Ostrowski Sisse Rye , Niemann Carsten U.
Published: May 2024

Supplementary Figure S3. Changes in innate immune cell subsets during targeted treatment and correlations with stimulated cytokine responses.
Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study
Authors: Bazarbachi Ali , Labopin Myriam , Moukalled Nour , Kröger Nicolaus , Rautenberg Christina , Schetelig Johannes , Finke Jürgen , Blau Igor Wolfgang , Blaise Didier , Stelljes Matthias , Eder Matthias , Platzbecker Uwe , Dreger Peter , Bethge Wolfgang , Tischer Johanna , Burns David , Sengeloev Henrik , Brissot Eolia , Giebel Sebastian , Nagler Arnon , Ciceri Fabio , Mohty Mohamad
Published: May 2024

GRFS for the total cohort (A), subgroup with CR1 (B), subgroup with CR2 (C) and those with active disease (D)
Supplementary Video S7 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Video S7. Meso^CD19 CAR T cells on CAF
Supplementary Table S3 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Authors: Anderson Thomas M. , Chang Bryan H. , Huang Alexander C. , Xu Xiaowei , Yoon Daniel , Shang Catherine G. , Mick Rosemarie , Schubert Erin , McGettigan Suzanne , Kreider Kristin , Xu Wei , Wherry E. John , Schuchter Lynn M. , Amaravadi Ravi K. , Mitchell Tara C. , Farwell Michael D.
Published: May 2024

Supplementary Table S3. PET imaging results and response assessments for all patients.
Supplementary Figure S5 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Authors: Anderson Thomas M. , Chang Bryan H. , Huang Alexander C. , Xu Xiaowei , Yoon Daniel , Shang Catherine G. , Mick Rosemarie , Schubert Erin , McGettigan Suzanne , Kreider Kristin , Xu Wei , Wherry E. John , Schuchter Lynn M. , Amaravadi Ravi K. , Mitchell Tara C. , Farwell Michael D.
Published: May 2024

Supplementary Figure S5. Change in SUVmax in patients with <10 days between PET0 and therapy start.
Supplementary Figure S4 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma
Authors: Anderson Thomas M. , Chang Bryan H. , Huang Alexander C. , Xu Xiaowei , Yoon Daniel , Shang Catherine G. , Mick Rosemarie , Schubert Erin , McGettigan Suzanne , Kreider Kristin , Xu Wei , Wherry E. John , Schuchter Lynn M. , Amaravadi Ravi K. , Mitchell Tara C. , Farwell Michael D.
Published: May 2024

Supplementary Figure S4. Early FDG PET/CT guides patient management.
Supplementary Figure S4 from Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Authors: Wehrli Marc , Guinn Samantha , Birocchi Filippo , Kuo Adam , Sun Yi , Larson Rebecca C. , Almazan Antonio J. , Scarfò Irene , Bouffard Amanda A. , Bailey Stefanie R. , Anekal Praju Vikas , Montero Llopis Paula , Nieman Linda T. , Song Yuhui , Xu Katherine H. , Berger Trisha R. , Kann Michael C. , Leick Mark B. , Silva Harrison , Salas-Benito Diego , Kienka Tamina , Grauwet Korneel , Armstrong Todd D. , Zhang Rui , Zhu Qingfeng , Fu Juan , Schmidts Andrea , Korell Felix , Jan Max , Choi Bryan D. , Liss Andrew S. , Boland Genevieve M. , Ting David T. , Burkhart Richard A. , Jenkins Russell W. , Zheng Lei , Jaffee Elizabeth M. , Zimmerman Jacquelyn W. , Maus Marcela V.
Published: May 2024

Supplementary Figure S4. Still frames from live cell microscopy videos demonstrating reduced edge dynamics of meso^FAP CAR T-cells compared to controls and target cell layer on flow chamber of acoustic microscopy.
Supplementary Data 1 from Impact of Circulating Tumor Cell–Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer
Authors: Cho Hyungseok , Byun Seok-Soo , Son Nak-Hoon , Chung Jae Il , Seo Won Ik , Lee Chan Ho , Morgan Todd M. , Han Ki-Ho , Chung Jae-Seung
Published: May 2024

Supplementary file
Data from Therapeutic Targeting of TIM-4-L with Engineered T Cells for Acute Myeloid Leukemia
Authors: Cieniewicz Brandon , Oliveira Edson , Saxton Mike , Torabi Damoun , Bhatta Ankit , Kukutla Phanidhar , Arballo Alexander , Yang Zhuo , Yu Bi , Fate Maria , Ning Hongxiu , Corey Lawrence , Maiti Abhishek , Corey Daniel
Published: May 2024

AbstractPurpose:
Disruption of lipid bilayer asymmetry is a common feature observed in cancer cells and offers novel routes for therapeutic targeting. We used the natural immune receptor TIM-4 to interrogate for loss of plasma membrane phospholipid polarity in primary acute myelogenous leukemia (AML) samples and evaluated the anti-leukemic activity of TIM-4-L–directed T-cell therapy in preclinical AML models.
Experimental Design:
We performed FACS analysis on 33 primary AML bone marrow specimens and correlated TIM-4-L expression frequency and intensity with molecular disease characteristics. Using Kasumi-1 and MV-4–11 AML cell lines, we further tested the anti-leukemic effects of TIM-4-L–directed engineered T cells in vitro and in vivo.
Results:
We found that 86% of untreated AML blasts displayed upregulation of cell surface TIM-4-L. These observations were agnostic to AML genetic classification, as samples with mutations in TP53, ASXL1, and RUNX1 displayed TIM-4-L upregulation similar to that seen in favorable and intermediate subtypes. TIM-4-L dysregulation was also stably present in AML cell lines. To evaluate the potential of targeting upregulated TIM-4-L with adoptive T-cell therapy, we constructed TIM-4-L–directed engineered T cells, which demonstrated potent anti-leukemic effects, effectively eliminating AML cell lines with a range of endogenous TIM-4-L expression levels both in vitro and in vivo.
Conclusions:
These results highlight TIM-4-L as a highly prevalent target on AML across a range of genetic classifications and novel target for T-cell–based therapy in AML. Further investigations into the role of TIM-4-L in AML pathogenesis and its potential as an anti-leukemic target for clinical development are warranted.
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance
Authors: Bugno Jason , Wang Liangliang , Yu Xianbin , Cao Xuezhi , Wang Jiaai , Huang Xiaona , Yang Kaiting , Piffko Andras , Chen Katherine , Luo Stephen Y. , Naccasha Emile , Hou Yuzhu , Fu Sherry , He Chuan , Fu Yang-xin , Liang Hua L. , Weichselbaum Ralph R.
Published: May 2024

Purpose:

Radiation-mediated immune suppression limits efficacy and is a barrier in cancer therapy. Radiation induces negative regulators of tumor immunity including regulatory T cells (Treg). Mechanisms underlying Treg infiltration after radiotherapy (RT) are poorly defined. Given that conventional dendritic cells (cDC) maintain Treg, we sought to identify and target cDC signaling to block Treg infiltration after radiation.

Experimental Design:

Transcriptomics and high dimensional flow cytometry revealed changes in murine tumor cDC that not only mediate Treg infiltration after RT but also associate with worse survival in human cancer datasets. Antibodies perturbing a cDC-CCL22-Treg axis were tested in syngeneic murine tumors. A prototype interferon–anti-epidermal growth factor receptor fusion protein (αEGFR-IFNα) was examined to block Treg infiltration and promote a CD8+ T cell response after RT.

Results:

Radiation expands a population of mature cDC1 enriched in immunoregulatory markers that mediates Treg infiltration via the Treg-recruiting chemokine CCL22. Blocking CCL22 or Treg depletion both enhanced RT efficacy. αEGFR-IFNα blocked cDC1 CCL22 production while simultaneously inducing an antitumor CD8+ T cell response to enhance RT efficacy in multiple EGFR-expressing murine tumor models, including following systemic administration.

Conclusions:

We identify a previously unappreciated cDC mechanism mediating Treg tumor infiltration after RT. Our findings suggest blocking the cDC1-CCL22-Treg axis augments RT efficacy. αEGFR-IFNα added to RT provided robust antitumor responses better than systemic free interferon administration and may overcome clinical limitations to interferon therapy. Our findings highlight the complex behavior of cDC after RT and provide novel therapeutic strategies for overcoming RT-driven immunosuppression to improve RT efficacy.

See related commentary by Kalinski et al., p. 4260
Table S4 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Authors: An Minae , Mehta Arnav , Min Byung Hoon , Heo You Jeong , Wright Samuel J. , Parikh Milan , Bi Lynn , Lee Hyuk , Kim Tae Jun , Lee Song-Yi , Moon Jeonghyeon , Park Ryan J. , Strickland Matthew R. , Park Woong-Yang , Kang Won Ki , Kim Kyoung-Mee , Kim Seung Tae , Klempner Samuel J. , Lee Jeeyun
Published: May 2024

Annotated cNMF programs
Figure S20 from Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer
Authors: An Minae , Mehta Arnav , Min Byung Hoon , Heo You Jeong , Wright Samuel J. , Parikh Milan , Bi Lynn , Lee Hyuk , Kim Tae Jun , Lee Song-Yi , Moon Jeonghyeon , Park Ryan J. , Strickland Matthew R. , Park Woong-Yang , Kang Won Ki , Kim Kyoung-Mee , Kim Seung Tae , Klempner Samuel J. , Lee Jeeyun
Published: May 2024

Figure S20. (A) CT imaging of tumor burden in a pair of patients classified as
either a responder with increased relative M1 ration or non-responder with
unchanged relative M1 ration. (B) CT scans of a second pair of patients as in (A).
(C) Multiplexed immunofluorescence (mIF) images of BL, FU1 and FU2 samples
from two patients, E17 (slow progressor) and E35 (fast progressor), staining for
panCK, PD-L1, CD163, CD68, CD14 and CD8.
Supplementary figure S4 from TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Authors: Tani Tetsuo , Mathsyaraja Haritha , Campisi Marco , Li Ze-Hua , Haratani Koji , Fahey Caroline G. , Ota Keiichi , Mahadevan Navin R. , Shi Yingxiao , Saito Shin , Mizuno Kei , Thai Tran C. , Sasaki Nobunari , Homme Mizuki , Yusuf Choudhury Fabliha B. , Kashishian Adam , Panchal Jipsa , Wang Min , Wolf Benjamin J. , Barbie Thanh U. , Paweletz Cloud P. , Gokhale Prafulla C. , Liu David , Uppaluri Ravindra , Kitajima Shunsuke , Cain Jennifer , Barbie David A.
Published: May 2024

Supplementary figureS4 shows the figures related to Figure 4.
Supplementary Figure S28 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Authors: Rosano Dalia , Sofyali Emre , Dhiman Heena , Ghirardi Chiara , Ivanoiu Diana , Heide Timon , Vingiani Andrea , Bertolotti Alessia , Pruneri Giancarlo , Canale Eleonora , Dewhurst Hannah F. , Saha Debjani , Slaven Neil , Barozzi Iros , Li Tong , Zemlyanskiy Grigory , Phillips Henry , James Chela , Győrffy Balázs , Lynn Claire , Cresswell George D. , Rehman Farah , Noberini Roberta , Bonaldi Tiziana , Sottoriva Andrea , Magnani Luca
Published: May 2024

Expression of epigenetic dormancy signature genes
Supplementary Figure S24 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Authors: Rosano Dalia , Sofyali Emre , Dhiman Heena , Ghirardi Chiara , Ivanoiu Diana , Heide Timon , Vingiani Andrea , Bertolotti Alessia , Pruneri Giancarlo , Canale Eleonora , Dewhurst Hannah F. , Saha Debjani , Slaven Neil , Barozzi Iros , Li Tong , Zemlyanskiy Grigory , Phillips Henry , James Chela , Győrffy Balázs , Lynn Claire , Cresswell George D. , Rehman Farah , Noberini Roberta , Bonaldi Tiziana , Sottoriva Andrea , Magnani Luca
Published: May 2024

Cell cycle regression of TRADITIOM MCF7 LSC for AI (–E2) arm
Supplementary Figure S21 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Authors: Rosano Dalia , Sofyali Emre , Dhiman Heena , Ghirardi Chiara , Ivanoiu Diana , Heide Timon , Vingiani Andrea , Bertolotti Alessia , Pruneri Giancarlo , Canale Eleonora , Dewhurst Hannah F. , Saha Debjani , Slaven Neil , Barozzi Iros , Li Tong , Zemlyanskiy Grigory , Phillips Henry , James Chela , Győrffy Balázs , Lynn Claire , Cresswell George D. , Rehman Farah , Noberini Roberta , Bonaldi Tiziana , Sottoriva Andrea , Magnani Luca
Published: May 2024

TRADITIOM MCF7 LSC of the TAM arm
Table S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Authors: Bashi Azadeh C. , Coker Elizabeth A. , Bulusu Krishna C. , Jaaks Patricia , Crafter Claire , Lightfoot Howard , Milo Marta , McCarten Katrina , Jenkins David F. , van der Meer Dieudonne , Lynch James T. , Barthorpe Syd , Andersen Courtney L. , Barry Simon T. , Beck Alexandra , Cidado Justin , Gordon Jacob A. , Hall Caitlin , Hall James , Mali Iman , Mironenko Tatiana , Mongeon Kevin , Morris James , Richardson Laura , Smith Paul D. , Tavana Omid , Tolley Charlotte , Thomas Frances , Willis Brandon S. , Yang Wanjuan , O'Connor Mark J. , McDermott Ultan , Critchlow Susan E. , Drew Lisa , Fawell Stephen E. , Mettetal Jerome T. , Garnett Mathew J.
Published: May 2024

Supplementary Table 2 lists drugs and drug combinations used
Table S11 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Authors: Bashi Azadeh C. , Coker Elizabeth A. , Bulusu Krishna C. , Jaaks Patricia , Crafter Claire , Lightfoot Howard , Milo Marta , McCarten Katrina , Jenkins David F. , van der Meer Dieudonne , Lynch James T. , Barthorpe Syd , Andersen Courtney L. , Barry Simon T. , Beck Alexandra , Cidado Justin , Gordon Jacob A. , Hall Caitlin , Hall James , Mali Iman , Mironenko Tatiana , Mongeon Kevin , Morris James , Richardson Laura , Smith Paul D. , Tavana Omid , Tolley Charlotte , Thomas Frances , Willis Brandon S. , Yang Wanjuan , O'Connor Mark J. , McDermott Ultan , Critchlow Susan E. , Drew Lisa , Fawell Stephen E. , Mettetal Jerome T. , Garnett Mathew J.
Published: May 2024

Supplementary Table 11 lists combination drug categories
Supplementary Figures S1-S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Authors: Bashi Azadeh C. , Coker Elizabeth A. , Bulusu Krishna C. , Jaaks Patricia , Crafter Claire , Lightfoot Howard , Milo Marta , McCarten Katrina , Jenkins David F. , van der Meer Dieudonne , Lynch James T. , Barthorpe Syd , Andersen Courtney L. , Barry Simon T. , Beck Alexandra , Cidado Justin , Gordon Jacob A. , Hall Caitlin , Hall James , Mali Iman , Mironenko Tatiana , Mongeon Kevin , Morris James , Richardson Laura , Smith Paul D. , Tavana Omid , Tolley Charlotte , Thomas Frances , Willis Brandon S. , Yang Wanjuan , O'Connor Mark J. , McDermott Ultan , Critchlow Susan E. , Drew Lisa , Fawell Stephen E. , Mettetal Jerome T. , Garnett Mathew J.
Published: May 2024

Supplementary Figure 1: Additional overview of screen and quality control.

Supplementary Figure 2: Combination benefit in combination-cell line pairs.

Supplementary Figure 3: Biomarkers of single agent and combination activity.

Supplementary Figure 4: Combination activity of venetoclax plus AZD5991 in AML cell
lines.

Supplementary Figure 5: Combination activity by cancer type for AZD5991 + AZ3202.

Supplementary Figure 6: Venetoclax + selumetinib and AZD5991 + selumetinib activity by cancer type.

Supplementary Figure 7: Venetoclax + selumetinib and AZD5991 + selumetinib activity by cancer type.

Supplementary Figure 8: Effect of MEK1/2 plus BCL2 inhibition on cell viability in AML cells.

Supplementary Figure 9: Effect of MEK1/2 plus MCL1 inhibition on cell viability in AML cells.

Supplementary Figure 10: Cancer type selectivity of venetoclax + AZD2811.

Supplementary Figure 11: Effect of Aurora kinase B or pan Aurora kinase plus BCL2 inhibition on cell viability in DLBCL cell lines.

Supplementary Figure 12: network analysis of AZD2811 plus venetoclax biomarkers and targets, and cancer type selectivity of AZD5991 + AZD5363.

Supplementary Figure 13: Further analysis of capivasertib (AZD5363) plus AZD5991 in endometrial cell lines.

Supplementary Figure 14: Effect of pan AKT inhibition plus MCL1 inhibition on cell viability in endometrial cell lines.

Supplementary Figure 15: Further analysis of capivasertib (AZD5363) plus AZD5991 and other inhibitors in endometrial cell lines.

Supplementary Figure 16: Effect of MCL1 genetic knockdown plus pan AKT inhibition on cell viability in endometrial cancer cell lines.
Figure 5 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Authors: Bashi Azadeh C. , Coker Elizabeth A. , Bulusu Krishna C. , Jaaks Patricia , Crafter Claire , Lightfoot Howard , Milo Marta , McCarten Katrina , Jenkins David F. , van der Meer Dieudonne , Lynch James T. , Barthorpe Syd , Andersen Courtney L. , Barry Simon T. , Beck Alexandra , Cidado Justin , Gordon Jacob A. , Hall Caitlin , Hall James , Mali Iman , Mironenko Tatiana , Mongeon Kevin , Morris James , Richardson Laura , Smith Paul D. , Tavana Omid , Tolley Charlotte , Thomas Frances , Willis Brandon S. , Yang Wanjuan , O'Connor Mark J. , McDermott Ultan , Critchlow Susan E. , Drew Lisa , Fawell Stephen E. , Mettetal Jerome T. , Garnett Mathew J.
Published: May 2024

AZD2811 plus venetoclax combination in DLBCL. A, Combo Emax versus HSA in 25 B-cell NHL cell lines including 11 DLBCL cell lines. Cell lines with high combination activity (combo Emax > 0.5 and HSA > 0.1) are in red. B, Growth inhibition and HSA excess matrices in DLBCL cell line WSUDLCL2. C, Western blot analysis for cleaved PARP in WSUDLCL2 cells treated with AZD2811 or venetoclax alone or in combination. D, Matrix plots indicating combination activity (measured by growth inhibition) in WSUDLCL2 cells pretreated with pan caspase inhibitor Q-VD-OPH and exposed to AZD2811 combined with venetoclax for 72 hours. Matrix values represent cell viability normalized to day 0 on the scale of 0 to 200 (value < 100 = percentage of growth inhibition, value > 100 = cell death). E, Tumor growth in WSUDLCL2 xenografts treated with AZD2811 or venetoclax alone or in combination for 46 days (n = 6 per group, * 0.05 < P < 0.01, ** 0.01 < P < 0.001). Data are plotted as mean tumor volume ± SEM. PO, orally; QD, every day; QW, every week.
Figure S6 from EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Authors: Kuhlmann-Hogan Alexandra , Cordes Thekla , Xu Ziyan , Kuna Ramya S. , Traina Kacie A. , Robles-Oteíza Camila , Ayeni Deborah , Kwong Elizabeth M. , Levy Stellar , Globig Anna-Maria , Nobari Matthew M. , Cheng George Z. , Leibel Sandra L. , Homer Robert J. , Shaw Reuben J. , Metallo Christian M. , Politi Katerina , Kaech Susan M.
Published: May 2024

Figure S6: Single cell analysis of tumorigenesis in humans reveals rewired LUAD patient macrophage lipid and mitochondrial metabolism.
Data from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs
Authors: Pal Choudhuri Shreoshi , Girard Luc , Lim Jun Yi Stanley , Wise Jillian F. , Freitas Braeden , Yang Di , Wong Edmond , Hamilton Seth , Chien Victor D. , Kim Yoon Jung , Gilbreath Collin , Zhong Jun , Phat Sarah , Myers David T. , Christensen Camilla L. , Mazloom-Farsibaf Hanieh , Stanzione Marcello , Wong Kwok-Kin , Hung Yin P. , Farago Anna F. , Meador Catherine B. , Dyson Nicholas J. , Lawrence Michael S. , Wu Sihan , Drapkin Benjamin J.
Published: May 2024

Abstract
Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires cross-resistance after relapse. This transformation is nearly inevitable in patients but has been difficult to capture in laboratory models. Here, we present a preclinical system that recapitulates acquired cross-resistance, developed from 51 patient-derived xenograft (PDX) models. Each model was tested in vivo against three clinical regimens: cisplatin plus etoposide, olaparib plus temozolomide, and topotecan. These drug-response profiles captured hallmark clinical features of SCLC, such as the emergence of treatment-refractory disease after early relapse. For one patient, serial PDX models revealed that cross-resistance was acquired through MYC amplification on extrachromosomal DNA (ecDNA). Genomic and transcriptional profiles of the full PDX panel revealed that MYC paralog amplifications on ecDNAs were recurrent in relapsed cross-resistant SCLC, and this was corroborated in tumor biopsies from relapsed patients. We conclude that ecDNAs with MYC paralogs are recurrent drivers of cross-resistance in SCLC.
Significance:
SCLC is initially chemosensitive, but acquired cross-resistance renders this disease refractory to further treatment and ultimately fatal. The genomic drivers of this transformation are unknown. We use a population of PDX models to discover that amplifications of MYC paralogs on ecDNA are recurrent drivers of acquired cross-resistance in SCLC.

This article is featured in Selected Articles from This Issue, p. 695
Supplementary Figure 4 from Spatial Mapping of Hematopoietic Clones in Human Bone Marrow
Authors: Young Andrew L. , Davis Hannah C. , Cox Maggie J. , Parsons Tyler M. , Burkart Samantha C. , Bender Diane E. , Sun Lulu , Oh Stephen T. , Challen Grant A.
Published: May 2024

Supplementary Figure 4. Imaging mass cytometry of bone marrow from UPN978825 showing the spatial organization of CD71+ erythroblasts, CD15+ myeloid cells and CD61+ megakaryocytes. Contiguous clusters of CD71+ erythroblasts appear distinct from other populations of cells. CD71+ does not appear to co-stain with other cell types.
Supplementary Figure 1 from Spatial Mapping of Hematopoietic Clones in Human Bone Marrow
Authors: Young Andrew L. , Davis Hannah C. , Cox Maggie J. , Parsons Tyler M. , Burkart Samantha C. , Bender Diane E. , Sun Lulu , Oh Stephen T. , Challen Grant A.
Published: May 2024

Supplementary Figure 1. Clustering of single cells by immunophenotypic profile and colored by cell type (left facet) and compared to the relative expression of key hematopoietic markers for stem/progenitor cells (CD34 and CD38), the malignant cells (CD71 and CD141), B-cells (CD19 and CD10), T-cells (CD3, CD4 and CD8) (right facets).
Figure S9 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Authors: Olesinski Elyse A. , Bhatia Karanpreet Singh , Wang Chuqi , Pioso Marissa S. , Lin Xiao Xian , Mamdouh Ahmed M. , Ng Shu Xuan , Sandhu Vedant , Jasdanwala Shaista Shabbir , Yilma Binyam , Bohl Stephan , Ryan Jeremy A. , Malani Disha , Luskin Marlise R. , Kallioniemi Olli , Porkka Kimmo , Adamia Sophia , Chng Wee Joo , Osato Motomi , Weinstock David M. , Garcia Jacqueline S. , Letai Anthony , Bhatt Shruti
Published: May 2024

Supplemental Figure 9 shows FLT-3 ITD+ AML cell lines and PDX models are sensitive to FLT-3 inhibitors identified by DBP across compartments.
Data from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Authors: Olesinski Elyse A. , Bhatia Karanpreet Singh , Wang Chuqi , Pioso Marissa S. , Lin Xiao Xian , Mamdouh Ahmed M. , Ng Shu Xuan , Sandhu Vedant , Jasdanwala Shaista Shabbir , Yilma Binyam , Bohl Stephan , Ryan Jeremy A. , Malani Disha , Luskin Marlise R. , Kallioniemi Olli , Porkka Kimmo , Adamia Sophia , Chng Wee Joo , Osato Motomi , Weinstock David M. , Garcia Jacqueline S. , Letai Anthony , Bhatt Shruti
Published: May 2024

Abstract
In many cancers, mortality is associated with the emergence of relapse with multidrug resistance (MDR). Thus far, the investigation of cancer relapse mechanisms has largely focused on acquired genetic mutations. Using acute myeloid leukemia (AML) patient-derived xenografts (PDX), we systematically elucidated a basis of MDR and identified drug sensitivity in relapsed AML. We derived pharmacologic sensitivity for 22 AML PDX models using dynamic BH3 profiling (DBP), together with genomics and transcriptomics. Using in vivo acquired resistant PDXs, we found that resistance to unrelated, narrowly targeted agents in distinct PDXs was accompanied by broad resistance to drugs with disparate mechanisms. Moreover, baseline mitochondrial apoptotic priming was consistently reduced regardless of the class of drug-inducing selection. By applying DBP, we identified drugs showing effective in vivo activity in resistant models. This study implies evasion of apoptosis drives drug resistance and demonstrates the feasibility of the DBP approach to identify active drugs for patients with relapsed AML.
Significance:
Acquired resistance to targeted therapy remains challenging in AML. We found that reduction in mitochondrial priming and common transcriptomic signatures was a conserved mechanism of acquired resistance across different drug classes in vivo. Drugs active in vivo can be identified even in the multidrug resistant state by DBP.
Alergia à penicilina
Authors: Croce Julio
Published: May 2024

O autor nos mostra as principais características e eventos da reação alérgica à penicilina, analisando seus aspectos químicos e imunológicos e os métodos disponíveis de como evitá-la.
Fatores associados ao baixo peso ao nascer: um estudo retrospectivo
Authors: Boscolo João Paulo Galiego , Cavichio Luciano Renato , Mahayri Nazira , Barros Vicente José Camargo , Bacha Angela Maria , Grassiotto Oswaldo Rocha
Published: May 2024

Foram estudadas retrospectivamente 26 variáveis referentes a aspectos pré-concepcionais, da gravidez, do parto e do recém-nascido, em 804 partos únicos ocorridos consecutivamente no Serviço de Obstetrícia da FCM/UNICAMP, entre julho de 1978 e março de 1979, em suas relações com o parto de recém nascidos com peso inferior a 2500 gramas. Este evento se evidenciou em 17,5% dos casos; a taxa de prematuridade foi de 12,8% e a freqüência de recém-nascidos a termo com retardo de crescimento intra uterino foi de 7,7%.As variáveis que consistentemente se associaram com maiores freqüências de baixo peso ao nascer foram também estudadas buscando identificar a sua atuação em termos de induzir prematuridade e/ou retardo de crescimento intra uterino.Discute-se à luz dos conhecimentos atuais o papel de cada variável atuando na gênese do baixo peso, atentando-se sempre para a realidade sócio-econômica e de saúde que envolve a população estudada.
Estado atual da estimulação cardíaca artificial
Authors: Costa Roberto , Stolf Noedir Antonio Groppo
Published: May 2024

A estimulação cardíaca artificial é o método de escolha para o tratamento das bradiarritmias sintomáticas ou que apresentem risco de vida. Está indicada na disfunção sinusal, nos bloqueios da condução átrio-ventricular do 2o grau tipo Mobitz II e do 3o grau adquiridos, e nos pacientes portadores de bloqueios fasciculares associados, cuja lesão anatômica esteja localizada abaixo do feixe de His.A eficácia do método está relacionada principalmente à escolha adequada do sistema de estimulação que cada paciente deverá receber. De uma maneira geral os pacientes com indicações profiláticas e os portadores de bloqueios do 2º e 3º grau sem alterações miocárdicas ou coronarianas deverão receber sistemas ventriculares enquanto que os pacientes portadores de coronariopatias ou miocardiopatias associadas, assim como os portadores de disfunção sinusal deverão receber sistemas fisiológicos.
A. W. Schlegel e G. W. F. Hegel como precursores da tratativa da Arte na Estética contemporânea
Authors: Rabelo Rodrigo C. , Weber José Fernandes
Published: May 2024

Tendo como ponto de partida o modo como Platão e Adorno abordam os desafios impostos pela arte à filosofia, o artigo busca destacar a mudança, que vai da “submissão da arte” (Platão) à crítica da estética clássica pela arte contemporânea (Adorno). A fim de avaliar o alcance da posição adorniana, segundo a qual contemporaneamente seria preciso partir da arte para fazer estética, centra seus esforços em mostrar como, já nos Cursos de estética, de Hegel, e na Doutrina da arte, de August Schlegel, tratava-se de reconhecer legitimidade à arte a partir da sua especificidade. São quatro os tópicos, em ambas as estéticas, que permitem sustentar tal afirmação: 1. A crítica à doutrina da arte apenas como mímesis; 2. A recusa à simples técnica artesanal-poética como constituindo uma estética filosófica; 3. O desenvolvimento do historicismo e da dialética como método de investigação filosófico da arte; 4. O desenvolvimento da estética comparada (entre as artes e gêneros). Por fim, busca-se mostrar brevemente alguns pontos de conexão entre as estéticas de Hegel e de August Schlegel com a estética contemporânea.
Jardim e paisagem entre a literatura e a filosofia da Época de Goethe
Authors: Arraes Esdras
Published: May 2024

O artigo procura refletir sobre a articulação da ideia de natureza proposta na Goethezeit (Época de Goethe, 1749-1832) e sua representação em jardim e paisagem. Nesse período, natureza, paisagem e jardim tornaram-se temas de romances, tratados e críticas que pretendiam compreender a sociedade de então. Tendo isso em conta, a narrativa do ensaio inicialmente aborda as duas modalidades de jardim do século XVIII – jardim francês e jardim-paisagem – e suas conexões com a literatura de Goethe e Julie la nouvelle Héloïse, obra do filósofo Jean-Jacques Rousseau. Em seguida, são consideradas brevemente duas críticas de Schiller centradas em refletir como o jardim e a paisagem expressam a liberdade humana. Para tanto, ele propõe a criação de um “jardim estético”, o qual seria a unificação entre natureza e história.
Modeling the Impact of Biomarker-Guided Versus ASCVD Risk–Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004
Authors: Foti Kathryn , Wang Dan , Tang Olive , Daya Natalie R. , Commodore-Mensah Yvonne , Juraschek Stephen P. , Christenson Robert H. , Selvin Elizabeth , McEvoy John W.
Published: May 2024

BACKGROUND:

Guidelines recommend antihypertensive medication for adults with both stage 1 hypertension (systolic blood pressure, 130–139 mm Hg or diastolic blood pressure, 80–89 mm Hg) and 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥10%. Cardiac biomarkers could facilitate a more targeted approach to the treatment of stage 1 hypertension.

METHODS:

We studied 1999 to 2004 National Health and Nutrition Examination Survey participants aged ≥20 years with untreated stage 1 hypertension without heart failure or ASCVD. We measured hs-cTnI (high-sensitivity cardiac troponin I), hs-cTnT (high-sensitivity cardiac troponin T) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in stored serum. We used the Pooled Cohort Equations to predict 10-year ASCVD risk. All participants had linked mortality follow-up through December 31, 2019.

RESULTS:

Overall, 17.5% of US adults (32.2 million) had untreated stage 1 hypertension. Among these 32.2 million persons, 15.7% had ASCVD risk ≥10%, 5.6% had elevated hs-cTnI, 4.7% had elevated hs-cTnT, and 9.5% had elevated NT-proBNP. Among adults aged 65 to 79 years with untreated stage 1 hypertension, 80.5% had ASCVD risk ≥10%, 13.0% had elevated hs-cTnI, 15.2% had elevated hs-cTnT, and 29.4% had elevated NT-proBNP. Less than half of the adults aged ≥80 years with untreated stage 1 hypertension had elevated biomarkers. The cardiovascular disease mortality rates among all adults with untreated stage 1 hypertension and with either ASCVD risk ≥10%, elevated hs-cTnI, elevated hs-cTnT, or elevated NT-proBNP were 7.51, 7.74, 8.75, and 5.87 per 1000 person-years, respectively.

CONCLUSIONS:

Cardiac biomarkers may be more selective for informing risk-based treatment decisions in stage 1 hypertension, particularly among adults aged ≥65 years.
Hypertension Impacts the Oscillatory Dynamics Serving the Encoding Phase of Verbal Working Memory
Authors: Arif Yasra , Killanin Abraham D. , Zhu Jingqi , Willett Madelyn P. , Okelberry Hannah J. , Johnson Hallie J. , Wilson Tony W.
Published: May 2024

BACKGROUND:

Chronic hypertension is known to be a major contributor to cognitive decline, with executive function and working memory being among the domains most commonly affected. Despite the growing literature on such dysfunction in patients with hypertension, the underlying neural processes are poorly understood.

METHODS:

In this cross-sectional study, we examine these neural processes by having participants with controlled hypertension, uncontrolled hypertension, and healthy controls perform a verbal working memory task during magnetoencephalography. Neural oscillations associated with the encoding and maintenance components of the working memory task were imaged and statistically evaluated among the 3 groups.

RESULTS:

Differences related to hypertension emerged during the encoding phase, where the hypertension groups exhibited weaker α-β oscillatory responses compared with controls in the left parietal cortices, whereas such oscillatory activity differed between the 2 hypertension groups in the right prefrontal regions. Importantly, these neural responses in the prefrontal and parietal cortices during encoding were also significantly associated with behavioral performance across all participants.

CONCLUSIONS:

Overall, our data suggest that hypertension is associated with neurophysiological abnormalities during working memory encoding, whereas the neural processes serving maintenance seem to be preserved. The right hemispheric neural responses likely reflected compensatory processing, which patients with controlled hypertension may use to achieve verbal working memory function at the level of controls, as opposed to the uncontrolled hypertension group where diminished resources may have limited such additional recruitment.
Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE
Authors: Chen Chih-Hao , Shoamanesh Ashkan , Colorado Pablo , Saad Feryal , Lemmens Robin , De Marchis Gian Marco , Caso Valeria , Xu Lizhen , Heenan Laura , Masjuan Jaime , Christensen Hanne , Connolly Stuart J. , Khatri Pooja , Mundl Hardi , Hart Robert G. , Smith Eric E.
Published: May 2024

BACKGROUND:

In the phase 2 PACIFIC-STROKE trial (Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Noncardioembolic Stroke), asundexian, an oral factor XIa inhibitor, did not increase the risk of hemorrhagic transformation (HT). In this secondary analysis, we aimed to investigate the frequency, types, and risk factors of HT on brain magnetic resonance imaging (MRI).

METHODS:

This was a secondary analysis of the PACIFIC-STROKE trial. Patients with mild-to-moderate acute noncardioembolic ischemic stroke were randomly assigned to asundexian or placebo plus guideline-based antiplatelet therapy. Brain MRIs were required at baseline (≤120 hours after stroke onset) and at 26 weeks or end-of-study. HT was defined using the Heidelberg classification and classified as early HT (identified on baseline MRI) or late HT (new HT by 26 weeks) based on iron-sensitive sequences. Multivariable logistic regression models were used to test factors that are associated with early HT and late HT, respectively.

RESULTS:

Of 1745 patients with adequate baseline brain MRI (mean age, 67 years; mean National Institutes of Health Stroke Scale score, 2.8), early HT at baseline was detected in 497 (28.4%). Most were hemorrhagic infarctions (hemorrhagic infarction type 1: 15.2%; HI2: 12.7%) while a few were parenchymal hematomas (parenchymal hematoma type 1: 0.4%; parenchymal hematoma type 2: 0.2%). Early HT was more frequent with longer symptom onset-to-MRI interval. Male sex, diabetes, higher National Institutes of Health Stroke Scale large (>15 mm) infarct size, cortical involvement by infarct, higher number of acute infarcts, presence of chronic brain infarct, cerebral microbleed, and chronic cortical superficial siderosis were independently associated with early HT in the multivariable logistic regression model. Of 1507 with follow-up MRI, HT was seen in 642 (42.6%) overall, including 361 patients (23.9%) with late HT (new HT: 306; increased grade of baseline HT: 55). Higher National Institutes of Health Stroke Scale, large infarct size, cortical involvement of infarct, and higher number of acute infarcts predicted late HT.

CONCLUSIONS:

About 28% of patients with noncardioembolic stroke had early HT, and 24% had late HT detectable by MRI. Given the high frequency of HT on MRI, more research is needed on how it influences treatment decisions and outcomes.
The Jurisdiction of Investment Tribunals to Adjudicate Claims and Incidental Questions Grounded in Domestic Law
Authors: Brosseau Jonathan
Published: May 2024

Over the past thirty years, arbitral tribunals tasked with determining their jurisdiction to adjudicate domestic law in investment disputes have frequently relied on one or a combination of two conventional approaches. The first approach interprets jurisdiction and applicable law provisions as serving separate functions and operating independently. The second approach contends that domestic law applies as a fact.

However, these two approaches fall short in encompassing the distinct ways in which domestic law can apply in an investment dispute. This application of domestic law is contingent on the stipulations found within a jurisdiction provision – often referred to as the “arbitration agreement” – and the jurisdictional provisions that delineate a tribunal’s personal, material, and temporal scope of jurisdiction.

To comprehensively elucidate how domestic law operates in investment arbitration, this article outlines the sources of a tribunal’s jurisdiction to adjudicate a claim and an incidental question grounded in domestic law. Firstly, the narrow or broad scope of a jurisdiction provision within an international investment agreement, domestic investment law, or investment contract determines whether a tribunal has the jurisdiction to hear a claim grounded in domestic law, pursuant to the severability doctrine. Secondly, the direct reference or lacuna in a jurisdictional provision determines whether a tribunal possesses jurisdiction to hear an incidental question grounded in domestic law, as a necessary and ancillary legal issue that a tribunal must preliminarily address to resolve the relevant claim, pursuant to the lex specialis principle.

Given these considerations, tribunals and treaty drafters should not rely on the two conventional approaches, but should consider any stipulation within a jurisdiction provision and jurisdictional provisions concerning the application of domestic law as the legal foundation of a claim and an incidental question.
Apparent total tract digestibility of calcium and phosphorus from partially defatted Hermetia illucens larvae meal in pigs
Authors: Grundmann S.M. , Herrero-Encinas J. , Eder K.
Published: May 2024

Insect meals, which have emerged as a sustainable protein source in animal nutrition, are also rich in calcium and phosphorus and thus might be a valuable source for supplying these minerals in farm animals. The aim of the present study was to determine the apparent total tract digestibility (ATTD) of these minerals from commercially available partially defatted meals of Hermetia illucens (HI) larvae in growing pigs. According to a difference approach, twenty male growing pigs with an average body weight of around 30 kg were divided into five groups of four pigs each and fed either a basal diet or the basal diet blended with one of three HI meals or monocalcium phosphate (MCP, as a positive control) for 14 days. Calcium and phosphorus ATTD were determined, by using the indicator method with acid-insoluble ash as an indigestible marker. Calcium ATTD on average of the three HI meals was 71.2%, ranging from 60.7% to 77.0%, and the ATTD of phosphorus was 80.6%, with a range of 70.8% to 88.9%. Calcium and phosphorus ATTD of MCP were 95.0% and 82.8%, respectively. The study shows that calcium and phosphorus from HI meals exhibit a relatively high ATTD in pigs, similar to that observed from inorganic mineral sources. Thus, HI meal could substantially contribute to the supply of calcium and phosphorus to pigs, thus opening the possibility to conserve scarce minerals resources such as phosphate-rich rocks for pig nutrition.
Description of immature stages of Endochironomus pekanus (Kieffer) (Diptera, Chironomidae)
Authors: LI ZIXUAN , TANG HONGQU
Published: May 2024

The larva and pupa of Endochironomus pekanus (Kieffer, 1916) are described for the first time based on the pharate materials from China. Endotribelos redimiculum Qi, Shi, Lin et Wang, 2013 is newly synonymized with E. pekanus based on reexamination of the type material. New distribution records are also given for the species here.
Synthesis of Pyrano[2,3-d]Pyrimidine Diones Catalyzed by Cobalt-Doped Iron Tartrate Nanomaterial: A Sustainable and Efficient Approach
Authors: Walle Mahesh , Kamble Snehal , Vibhute Baliram , Pawar Rajendra , Ingle Rajita , Mahmoud Mohamed H. , Abd El-Salam Nasser M. , Fouad H.
Published: May 2024

This study presents a novel and environmentally sustainable approach for the one-pot multicomponent green synthesis of pyrano[2,3-d]pyrimidine dione derivatives. The devised procedure involves a three-component condensation of aldehydes, malononitrile, and barbituric acid, employing
a nanomaterial catalyst in the form of cobalt-doped iron tartrate. This catalyst, characterized by its nanoscale dimensions, demonstrates exceptional reusability and water solubility, contributing to its eco-friendly profile. The synthesis is conducted under reflux conditions, optimizing the
reaction efficiency. Key attributes of the proposed protocol include the use of a non-toxic, cost-effective, and readily available catalyst. The high atom economy of the reaction signifies minimal waste generation, enhancing the sustainability of the synthetic process. Additionally, the reaction
features a short duration, aligning with the principles of efficiency and resource conservation. Notably, the utilization of water as the solvent further enhances the green approach, minimizing the environmental impact. This innovative synthesis protocol not only addresses the growing demand
for environmentally conscious methodologies but also showcases the potential for scalable and practical applications in organic synthesis. The integration of a reusable nanomaterial catalyst, coupled with the adoption of water as a solvent, positions this approach as a promising advancement
in the pursuit of sustainable and green chemical practices. The study provides valuable insights into the development of efficient and environmentally benign synthetic routes for the production of pyrano[2,3-d]pyrimidine dione derivatives, paving the way for the exploration of greener alternatives
in the realm of organic chemistry.
Eco-Synthesis of Gold Nanoparticles Using Vigna unguiculata Seed Extract: A Leap in the Direction of Antiglycation Remedies
Authors: Alsukaibi Abdulmohsen K. D. , Khan Salman , Ali Khan Mohd Wajid , Rafi Zeeshan , Al-Otaibi Ahmed , Alshamari Asma K. A. A. , Kaur Kirtanjot , Mechi Lassaad , Alimi Fathi Rabeh , Alshammari Eida M. , Pandey Ramendra Pati , Umar Ahmad , Ahmad Saheem
Published: May 2024

Nanotechnology, an interdisciplinary field that merges physics, chemistry, and biology, has emerged as a catalyst for innovation, offering far-reaching implications across various scientific disciplines. Gold nanoparticles (GNPs), with their unique physicochemical properties and biocompatibility,
have become a focal point in this technological revolution. This research delves into the eco-friendly synthesis of gold nanoparticles using Vigna unguiculata seed extract, a botanical resource known for its rich phytochemical composition. The study investigates the antiglycation activities
of these nanoparticles, drawing insights from existing literature. The synthesis process involves the reduction of gold ions by the bioactive compounds present in the Vigna unguiculata seed extract (VuS), leading to the formation of Vigna unguiculata derived GNPs (V-GNPs). Comprehensive
characterization techniques, including UV-Vis spectroscopy and transmission electron microscopy, were employed to confirm the stability, size, and shape of the synthesized nanoparticles. The research aligns with recent studies suggesting the potential of gold nanoparticles in mitigating glycation-related
disorders. Glycation is a biochemical process implicated in various health complications, particularly diabetes. The antiglycation properties of V-GNPs, as revealed in this study, present an intriguing avenue for managing diabetes and associated complications. The unique composition of V-GNPs,
coupled with their promising antiglycation properties, underscores their potential as effective therapeutic agents in the fight against diabetes and other glycation-related disorders. This research not only contributes to the existing body of knowledge but also opens up new possibilities for
the application of V-GNPs in the realm of nanomedicine.